Baxter International Inc. · NYSE:BAX
Baxter International — 43rd Annual J.P. Morgan Healthcare Conference (January 2025)
18 slides from Baxter International's conference presentation, Jan 13, 2025
Slide 1: 43rd Annual J.P. Morgan Healthcare Conference
43 RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE José (Joe) Almeida C h a i r, P r e s i d e n t & C h i e f E xe c u t i ve O f f i c e r JANUARY 13, 2025 1
Slide 2: Safe Harbor Statement
S A F E H A R B O R S TAT E M E N T This presentation includes forward-looking statements concerning the company’s financial results (including the outlook for full-year 2024 and full-year 2025) and business development, regulatory and operational activities (including the anticipated timing and imp
Slide 3: Non-GAAP Financial Measures
NON-GAAP FINANCIAL MEASURES This presentation contains certain forward-looking financial measures that are not calculated in accordance with U.S. GAAP (Generally Accepted Accounting Principles). The forward-looking non-GAAP financial measures include forward-looking adjusted operating margin guidanc
Slide 4: Unwavering in our mission of saving and sustaining lives
U N WAV E R I N G I N O U R MISSION OF S AV I N G A N D S U S TA I N I N G L I V E S 4
Slide 5: Business Highlights
BUSINESS HIGHLIGHTS Executing broad strategic transformation to enhance performance, accelerate innovation and drive incremental value for all stakeholders Benefitting from balanced and diversified portfolio to deliver results and advance our Mission Finalizing completion of pending sale of Kidney C
Slide 6: Progress update on strategic actions taken to deliver enhanced shareholder value
P R O G R E S S U P D AT E O N S T R AT E G I C A C T I O N S TA K E N T O D E L I V E R E N H A N C E D S H A R E H O L D E R VA L U E Complete Complete In Progress • Finalized operating model • Completed the divestiture • On Aug. 13, 2024, Baxter and in Q3 2023 began of the BioPharma Solutions and
Slide 7: Pending Vantive Sale: What's Next
P E N D I N G VA N T I V E S A L E : W H AT ’ S N E X T Regulatory submissions, clearances under way in global markets Transaction is currently expected to close early 20251 Baxter expects to receive approximately $3.50 billion in cash with net after-tax proceeds currently estimated to be in the ran
Slide 8: New Baxter: Increased agility, clearer focus and better positioned to invest for growth and innovation
N E W B A X T E R : I N C R E A S E D A G I L I T Y, C L E A R E R F O C U S A N D B E T T E R P O S I T I O N E D T O I N V E S T F O R G R O W T H A N D I N N O VAT I O N Medical Products & Therapies Healthcare Systems & Technologies Pharmaceuticals An essential healthcare partner with an unmatche
Slide 9: Medical Products & Therapies
MEDICAL PRODUCTS & THERAPIES1 Current Portfolio Near Term Launches2 Future Launches Novum IQ LVP & Syringe Infusion IQ Guardian (Digital) OUS3 Artificial Intelligence Novum IQ LVP Novum PCA Platform (Canada / U.S.) Gravity Developed Software to Set Rest of World U.S. & Help Identify Infusion Launche
Slide 10: Medical Products & Therapies
MEDICAL PRODUCTS & THERAPIES1 Current Portfolio Near Term Launches2 Future Launches Floseal with Recothrom Coseal Adhesion Geographic Expansion Reduction (Japan) Accureach MIS Advanced Introducer Surgery Hemopatch Room New Indications and Line Extensions Temperature U.S. PERCLOT GEM Monitor v3 1Not
Slide 11: Healthcare Systems & Technologies
H E A LT H C A R E S Y S T E M S & T E C H N O L O G I E S 1 Current Portfolio Near Term Launches2 Future Launches Helion Handsfree OR Integration Communication Connected Enhancements System Overhead Lift TS7000 Voalte System Robotic Table Nurse Call Precision Robotic Care & Locating Table Med Surg
Slide 12: Healthcare Systems & Technologies
H E A LT H C A R E S Y S T E M S & T E C H N O L O G I E S 1 Current Portfolio Near Term Launches2 Future Launches Vest APX RetinaVue with Innovative Airway LumineticsGo Intelligent Diagnostics BardyDX Disposable Clearance Therapy AI Diagnostic for Diabetic Smart Connected Early CAM Patch Blood Reti
Slide 13: Pharmaceuticals
PHARMACEUTICALS1 Current Portfolio Near Term Launches2 Future Launches Targeting ~10 new Injectables & Doxil Zosyn Sevoflurane Vasopressin Vancomycin Norepinephrine product launches Anesthesia per year Cyclophosphamide Daptomycin Ifosfamide Myxredlin Micafungin Ropivicaine Injection Drug Focused on
Slide 14: Strategic transformation designed to create a more streamlined, agile company focused on enhancing value
S T R AT E G I C T R A N S F O R M AT I O N D E S I G N E D T O C R E AT E A M O R E S T R E A M L I N E D , A G I L E C O M PA N Y F O C U S E D O N E N H A N C I N G VA L U E 1 • Targeting 4% - 5% operational sales growth annually • Driving sales growth faster than market through innovation and ma
Slide 15: Baxter (CO) Preliminary Operating Income Bridge
B A X T E R ( C O ) P R E L I M I N A R Y O P E R AT I N G I N C O M E B R I D G E 1 , 2 ~100 bps ~30 bps ~210 bps ~(60) bps ~250 bps ~(40) bps3 ~16.5% 13.7% to 13.8% Includes ~250 bps impact from stranded costs FY 2024 Net Benefit from TSA5 Hurricane Operational MSA5 Impact FY 2025 Adjusted and Cos
Slide 16: North Cove Strong
NORTH COVE STRONG 9 of 10 manufacturing lines restarted, with 10th September 29, 2024 line expected to resume imminently 9 plants activated across global network to help increase available inventory 100% allocation reached across majority of critical IV product groups by the end of 2024 ~200 airplan
Slide 17: Continuing Momentum In and Beyond 2025
C O N T I N U I N G M O M E N T U M I N 2 0 2 5 A N D B E YO N D Building on underlying 2024 business momentum and financial progress Assessing potential opportunities to exit select product and/or markets to further optimize portfolio and enhance performance Continuing to drive benefits from vertic
Slide 18: 43rd Annual J.P. Morgan Healthcare Conference
43 RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE José (Joe) Almeida C h a i r, P r e s i d e n t & C h i e f E xe c u t i ve O f f i c e r JANUARY 13, 2025 18
Baxter International — 43rd Annual J.P. Morgan Healthcare Conference (January 2025) on 6ix